Lonza Group AG (LZAGY)
| Market Cap | 42.75B -12.5% |
| Revenue (ttm) | 8.24B -1.6% |
| Net Income | -346.81M |
| EPS | -4.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 26.85 |
| Dividend | 0.40 (0.64%) |
| Ex-Dividend Date | May 13, 2026 |
| Volume | 3,719 |
| Open | 60.72 |
| Previous Close | 61.27 |
| Day's Range | 60.69 - 61.38 |
| 52-Week Range | 58.53 - 73.85 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
News
Lonza Group AG Earnings Call Transcript: Q1 2026
Q1 saw strong performance across all CDMO platforms, with 2026 sales growth guided at 11%-12% CER and CORE EBITDA margin above 32%. Divestment of CHI and robust CapEx progress support a pure-play CDMO focus, while proactive risk management and healthy demand underpin the outlook.
Lonza Group AG Earnings release: Q1 2026
Lonza Group AG released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Lonza Group AG Transcript: Investor update (Q&A)
A major portfolio transformation is complete with the divestment of 60% of CHI, focusing the business as a pure-play CDMO. Proceeds of at least CHF 3 billion will fund organic growth, bolt-on M&A, and a CHF 500 million share buyback, with 2026 guidance unchanged.
Lonza Group AG Press release: Investor update (Q&A)
Lonza Group AG issued a press release on March 9, 2026, disclosing material business information to investors.
Lonza Group AG Slides: Investor update (Q&A)
Lonza Group AG has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Lonza Group AG Transcript: Investor update
A major portfolio transformation is completed with the divestment of 60% of the CHI business, unlocking CHF 1.7 billion upfront and expected total proceeds of at least CHF 3 billion. Proceeds will fund organic growth, acquisitions, and a CHF 500 million share buyback, with the company now fully focused on its CDMO strategy and maintaining strong growth and margin outlooks.
Lonza Group AG Press release: Investor update
Lonza Group AG issued a press release on March 6, 2026, disclosing material business information to investors.
Lonza Group AG Slides: Investor update
Lonza Group AG has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the ...
Lonza Group AG Earnings Call Transcript: H2 2025
Delivered CHF 6.5 billion in sales (+21.7% constant currency), with core EBITDA margin up to 31.6% and free cash flow nearly doubling. Outlook for 2026 is 11%-12% sales growth and margin above 32%, supported by strong segment performance and disciplined capital allocation.
Lonza Group AG Annual report: H2 2025
Lonza Group AG has published its H2 2025 annual report on January 28, 2026.
Lonza Group AG Quarterly report: H2 2025
Lonza Group AG has published its H2 2025 quarterly earnings report on January 28, 2026.
Lonza Group AG Slides: H2 2025
Lonza Group AG has posted slides in relation to its H2 2025 quarterly earnings report, which was published on January 28, 2026.
Lonza Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A clear strategy and robust financial model underpin strong growth, with major investments in global capacity and technology. The Vacaville acquisition strengthens U.S. presence, while ongoing regionalization and high customer retention support long-term value creation.
Lonza Group AG Slides: 44th Annual J.P. Morgan Healthcare Conference
Lonza Group AG has posted slides in relation to its latest quarterly earnings report, which was published on January 13, 2026.
Lonza Group AG Earnings Call Transcript: Q3 2025
Strong Q3 performance and robust contracting support confirmation of 2025 outlook, with CDMO sales growth of 20–21% and margin of 30–31%. Vacaville and CHI businesses are progressing as planned, and growth projects remain on track despite FX and funding headwinds.
Lonza Group AG Earnings release: Q3 2025
Lonza Group AG released its Q3 2025 earnings on October 23, 2025, summarizing the period's financial results.
Lonza Group AG Earnings Call Transcript: H1 2025
Delivered strong H1 2025 results with 19% CER sales growth and upgraded full-year CDMO guidance to 20%-21% sales growth and 30%-31% core EBITDA margin. Integrated Biologics and Advanced Synthesis drove performance, while CHI recovery and major CapEx projects progressed.
Lonza Group AG Quarterly report: H1 2025
Lonza Group AG has published its H1 2025 quarterly earnings report on July 23, 2025.
Lonza Group AG Slides: H1 2025
Lonza Group AG has posted slides in relation to its H1 2025 quarterly earnings report, which was published on July 23, 2025.
Lonza Group AG Earnings Call Transcript: Q1 2025
Strong Q1 2025 performance supports a confirmed outlook for nearly 20% sales growth and a core EBITDA margin near 30%. Segment momentum is robust, with high asset utilization and ongoing growth projects, while risk from tariffs and FX is mitigated by global footprint and hedging.
Lonza Group AG Earnings release: Q1 2025
Lonza Group AG released its Q1 2025 earnings on May 9, 2025, summarizing the period's financial results.
Lonza Group AG Earnings Call Transcript: H2 2024
2024 results showed stable revenues at CHF 6.6 billion, with strong CDMO growth offsetting CHI declines. 2025 guidance anticipates CDMO revenue growth near 20% and margin expansion, supported by new capacity and the Vacaville acquisition.
Lonza Group AG Annual report: H2 2024
Lonza Group AG has published its H2 2024 annual report on January 29, 2025.
Lonza Group AG Quarterly report: H2 2024
Lonza Group AG has published its H2 2024 quarterly earnings report on January 29, 2025.